Cryptococcosis in solid-organ, hematopoietic stem cell, and tissue transplant recipients: Evidence-Based evolving trends

Clinical Infectious Diseases

Volumn 48, Issue 11, 2009, Pages 1566-1576

  Sun, Hsin Yun ^a,c   Wagener, Marilyn M ^b   Singh, Nina ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; AZATHIOPRINE; BUSULFAN; CASPOFUNGIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUCONAZOLE; FLUCYTOSINE; FLUDARABINE; KETOCONAZOLE; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY; AMPHOTERICIN B; ANTIFUNGAL AGENT;

CRYPTOCOCCOSIS; DRUG USE; EVIDENCE BASED PRACTICE; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HEMATOPOIETIC STEM CELL; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RECIPIENT; REVIEW; SURVIVAL RATE; TISSUE TRANSPLANTATION; ARTICLE; CHEMICALLY INDUCED DISORDER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CRYPTOCOCCOSIS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KIDNEY FAILURE; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; TISSUE TRANSPLANTATION;

EID: 66949141155     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/598936     Document Type: Review

References (124)

1. Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis 2001;7:375-81.
2. Singh N, Dromer F, Perfect JR, Lortholary O. Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis 2008;47:1321-7.
3. Singh N, Wagener MM, Marino IR, Gayowski T. Trends in invasive fungal infections in liver transplant recipients: correlation with evolution in transplantation practices. Transplantation 2002; 73:63-7.
4. Singh N. Impact of current transplantation practices on the changing epidemiology of infections in transplant recipients. Lancet Infect Dis 2003;3:156-61.
5. Singh N, Avery RK, Munoz P, et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 2003; 36:46-52.
6. Kontoyiannis DP, Marr K, Wannemuehler KA, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the TRANSNET database [abstract M-1196]. In: Program and abstracts of the 47th Inter- science Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2007:449.
7. Beyt BE Jr, Waltman SR. Cryptococcal endophthalmitis after corneal transplantation. N Engl J Med 1978; 298:825-6.
8. de Castro LE, Sarraf OA, Lally JM, Sandoval HP, Solomon KD, Vro- man DT. Cryptococcus albidus keratitis after corneal transplantation. Cornea 2005; 24:882-3.
9. Perry HD, Donnenfeld ED. Cryptococcal keratitis after keratoplasty. Am J Ophthalmol 1990; 110:320-1.
10. Perry HD, Doshi SJ, Donnenfeld ED, Bai GS. Topical cyclosporin A in the management of therapeutic keratoplasty for mycotic keratitis. Cornea 2002;21:161-3.
11. Ritterband DC, Seedor JA, Shah MK, Waheed S, Schorr I. A unique case of Cryptococcus laurentii keratitis spread by a rigid gas permeable contact lens in a patient with onychomycosis. Cornea 1998; 17:115-8.
12. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14.
13. Malek SK, Obmann MA, Gotoff RA, Foltzer MA, Hartle JE, Potdar S. Campath-1H induction and the incidence of infectious complications in adult renal transplantation. Transplantation 2006; 81:17-20.
14. Aberg JA, Mundy LM, Powderly WG. Pulmonary cryptococcosis in patients without HIV infection. Chest 1999; 115:734-40.
15. Abraham KA, Little MA, Casey R, Smyth E, Walshe JJ. A novel presentation of cryptococcal infection in a renal allograft recipient. Ir Med J 2000; 93:82-4.
16. Altiparmak MR, Apaydin S, Trablus S, et al. Systemic fungal infections after renal transplantation. Scand J Infect Dis 2002; 34:284-8.
17. Bruno KM, Farhoomand L, Libman BS, Pappas CN, Landry FJ. Cryp- tococcal arthritis, tendinitis, tenosynovitis, and carpal tunnel syndrome: report of a case and review of the literature. Arthritis Rheum 2002;47:104-8.
18. Kapoor A, Flechner SM, O'Malley K, Paolone D, File TM Jr, Cutrona AF. Cryptococcal meningitis in renal transplant patients associated with environmental exposure. Transpl Infect Dis 1999; 1:213-7.
19. Litmathe J, Feindt P, Boeken U, Mayer K, Althaus C, Gams E. Cryptococcus neoformans infection as scleral abscess in a cardiac allograft recipient 6 months after heart transplantation. Transplant Proc 2002; 34:3252-4.
20. Molino D, Salvatore De Santo L, Delfino M, et al. Anasarca caused by Cryptococcus neoformans after heart transplantation. J Heart Lung Transplant 2003; 22:478-83.
21. Ramanathan V, Kazancioglu R, Goral S, Dummer S, Helderman JH. Isolated pleural involvement by Cryptococcus in a kidney-pancreas transplant recipient. Nephrol Dial Transplant 2002; 17:321-2.
22. Wu G, Vilchez RA, Eidelman B, Fung J, Kormos R, Kusne S. Cryp- tococcal meningitis: an analysis among 5,521 consecutive organ transplant recipients. Transpl Infect Dis 2002; 4:183-8.
23. Akamatsu N, Sugawara Y, Nakajima J, Kishi Y, Kaneko J, Makuuchi M. Cryptococcosis after living donor liver transplantation: report of three cases. Transpl Infect Dis 2005; 7:26-9.
24. Alexander J, Limaye AP, Ko CW, Bronner MP, Kowdley KV. Association of hepatic iron overload with invasive fungal infection in liver transplant recipients. Liver Transpl 2006; 12:1799-804.
25. Basaran O, Emiroglu R, Arikan U, Karakayali H, Haberal M. Cryptococcal necrotizing fasciitis with multiple sites of involvement in the lower extremities. Dermatol Surg 2003; 29:1158-60.
26. Baumgarten KL, Valentine VG, Garcia-Diaz JB. Primary cutaneous cryptococcosis in a lung transplant recipient. South Med J 2004;97:692-5.
27. Bauza A, Redondo P, Rubio M. Primary cutaneous cryptococcal cel- lulitis secondary to insect bite in an immunosuppressed patient after liver transplantation. Clin Exp Dermatol 2005; 30:241-3.
28. Campos S, Caramori M, Teixeira R, et al. Bacterial and fungal pneumonias after lung transplantation. Transplant Proc 2008; 40:822-4.
29. Dipchand AI, Benson L, McCrindle BW, Coles J, West L. Mycophenolate mofetil in pediatric heart transplant recipients: a single- center experience. Pediatr Transplant 2001 ; 5:112-8.
30. Fairhurst RM, Pegues DA. Images in clinical medicine. Pulmonary cryptococcal granulomas. N Engl J Med 2002; 347:497.
31. Fishman JA, Gonzalez RG, Branda JA. Case records of the Massachusetts General Hospital. Case 11-2008: a 45-year-old man with changes in mental status after liver transplantation. N Engl J Med 2008;358:1604-13.
32. Geusau A, Sandor N, Messeritsch E, Jaksch P, Tintelnot K, Presterl E. Cryptococcal cellulitis in a lung-transplant recipient. Br J Dermatol 2005; 153:1068-70.
33. Gulati M, Kaur R, Jha V, Venkataramu NK, Gupta D, Suri S. Highresolution CT in renal transplant patients with suspected pulmonary infections. Acta Radiol 2000;41:237-41.
34. Gupta RK, Khan ZU, Nampoory MR, Mikhail MM, Johny KV. Cutaneous cryptococcosis in a diabetic renal transplant recipient. J Med Microbiol 2004; 53:445-9.
35. Hermann W, Gunther P, Berrouschot J, Kuhn HJ, Wagner A. Cryp- tococcal meningitis in a patient with systemic immunosuppression 13 years after liver transplantation. Intensive Care Med 2002; 28:1500.
36. Hill-Edgar AA, Nasr SH, Borczuk AC, D'Agati VD, Radhakrishnan J, Markowitz GS. A rare infectious cause ofrenal allograft dysfunction. Am J Kidney Dis 2002;40:1103-7.
37. Hunger RE, Paredes BE, Quattroppani C, Krahenbuhl S, Braathen LR. Primary cutaneous cryptococcosis in a patient with systemic im- munosuppression after liver transplantation. Dermatology 2000; 200:352-5.
38. Iacobellis FW, Jacobs MI, Cohen RP. Primary cutaneous cryptococcosis. Arch Dermatol 1979; 115:984-5.
39. Khan ZU, Chugh TD. Invasive fungal infections in Kuwait: a retrospective study. Indian J Chest Dis Allied Sci 2000; 42:279-87.
40. Ladoyanni E, Pereira M, Struthers K, et al. Disseminated Cryptococcus infection in a liver-transplant recipient presenting with a chronic scalp eruption. Clin Exp Dermatol 2008; 33:655-6.
41. Lanternier F, Chandesris MO, Poiree S, et al. Cellulitis revealing a cryptococcosis-related immune reconstitution inflammatory syndrome in a renal allograft recipient. Am J Transplant 2007; 7:2826-8.
42. Lee YA, Kim HJ, Lee TW, et al. First report of Cryptococcus albi- dus-induced disseminated cryptococcosis in a renal transplant recipient. Korean J Intern Med 2004; 19:53-7.
43. Levy PY, Habib G, Reynaud-Gaubert M, Raoult D, Rolain JM. Pericar- dial effusion due to Cryptococcus neoformans in a patient with cystic fibrosis following lung transplantation. Int J Infect Dis 2008; 12:452.
44. Lezaic V, Radivojevic D, Blagojevic-Lazic R, Djukanovic L. Infection of central nervous system after kidney transplantation. Transpl Infect Dis 2002;4:167-8.
45. Mehrenberger M, Kamar N, Borde JS, et al. Vertigo after renal transplantation: a sign of paucisymptomatic cryptococcal meningitis. Exp Clin Transplant 2006; 4:525-7.
46. Moe K, Lotsikas-Baggili AJ, Kupiec-Banasikowska A, Kauffman CL. The cutaneous predilection of disseminated cryptococcal infection in organ transplant recipients. Arch Dermatol 2005; 141:913-4.
47. Montoya JG, Giraldo LF, Efron B, et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis 2001; 33:629-40.
48. Mueller NJ, Fishman JA. Asymptomatic pulmonary cryptococcosis in solid organ transplantation: report of four cases and review of the literature. Transpl Infect Dis 2003;5:140-3.
49. Nath DS, Kandaswamy R, Gruessner R, Sutherland DE, Dunn DL, Humar A. Fungal infections in transplant recipients receiving alem- tuzumab. Transplant Proc 2005; 37:934-6.
50. Nicol AJ, Cassidy MJ, Michalowsky K, Kahn D. Use of intralipid as a vehicle for amphotericin B in the treatment of cryptococcal meningitis in a renal transplant recipient. Nephron 1996;73:312-3.
51. Nosanchuk JD, Shoham S, Fries BC, Shapiro DS, Levitz SM, Cas- adevall A. Evidence of zoonotic transmission of Cryptococcus neofor- mans from a pet cockatoo to an immunocompromised patient. Ann Intern Med 2000; 132:205-8.
52. Ortiz M, Gonzalez E, Munoz MA, Andres A. Cryptococcal monoar- thritis without systemic involvement in a renal transplant patient. Transplantation 2004; 78:301-2.
53. Pappas PG, Andes D, Schuster M, et al. Invasive fungal infections in low-risk liver transplant recipients: a multi-center prospective observational study. Am J Transplant 2006; 6:386-91.
54. Pasqualotto AC, Bittar AE, de Quadros M, Severo LC. Cryptococcal cellulitis in a renal transplant patient. Nephrol Dial Transplant 2005; 20:2007-8.
55. Pasqualotto AC, Bittencourt Severo C, de Mattos Oliveira F, Severo LC. Cryptococcemia: an analysis of 28 cases with emphasis on the clinical outcome and its etiologic agent. Rev Iberoam Micol 2004;21:143-6.
56. Peleg AY, Husain S, Kwak EJ, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007; 44:204-12.
57. Rabkin JM, Oroloff SL, Corless CL, et al. Association of fungal infection and increased mortality in liver transplant recipients. Am J Surg 2000; 179:426-30.
58. Rakvit A, Meyerrose G, Vidal AM, Kimbrough RC, Sarria JC. Cellulitis caused by Cryptococcus neoformans in a lung transplant recipient. J Heart Lung Transplant 2005; 24:642.
59. Rerolle JP, Szelag JC, Diaconita M, Paraf F, Aldigier JC, Le Meur Y.
60. Intracranial granuloma and skull osteolysis: complication ofa primary cutaneous cryptococcosis in a kidney transplant recipient. Am J Kidney Dis 2005;46:e113-7.
61. Sang H, Zhou WQ, Shi QL, Zhang XH, Ni RZ. Disseminated cryptococcosis with extensive subcutaneous nodules in a renal transplant recipient. Chin Med J (Engl) 2004; 117:1595-6.
62. Lai KK, Rosenberg AE. Case 19-1999-a 55-year-old man with a destructive bone lesion 17 months after liver transplantation. N Engl JMed 1999;340:1981-8.
63. Patel R, Portela D, Badley AD, et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 1996; 62:926-34.
64. Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med 2007;4:e21.
65. Utili R, Tripodi MF, Ragone E, et al. Hepatic cryptococcosis in a heart transplant recipient. Transpl Infect Dis 2004; 6:33-6.
66. Siddiqui TJ, Zamani T, Parada JP. Primary cryptococcal prostatitis and correlation with serum prostate specific antigen in a renal transplant recipient. J Infect 2005; 51:e153-7.
67. Silveira FP, Husain S, Kwak EJ, et al. Cryptococcosis in liver and kidney transplant recipients receiving anti-thymocyte globulin or alemtuzumab. Transpl Infect Dis 2007; 9:22-7.
68. Summers SA, Dorling A, Boyle JJ, Shaunak S. Cure of disseminated cryptococcal infection in a renal allograft recipient after addition of g-interferon to anti-fungal therapy. Am J Transplant 2005; 5:2067-9.
69. Van Grieken SA, Dupont LJ, Van Raemdonck DE, Van Bleyenbergh P, Verleden GM. Primary cryptococcal cellulitis in a lung transplant recipient. J Heart Lung Transplant 2007; 26:285-9.
70. Vo-Cong MT, Persu A, Marot L, Goffin E. The transplanted patient who suffered from excruciating lower limb pain and developed nodular skin lesions. Nephrol Dial Transplant 1999; 14:2947-9.
71. Xia D, Yan LN, Xu L, et al. Postoperative severe pneumonia in adult liver transplant recipients. Transplant Proc 2006; 38:2974-8.
72. Abbott KC, Hypolite I, Poropatich RK, et al. Hospitalizations for fungal infections after renal transplantation in the United States. Transpl Infect Dis 2001;3:203-11.
73. Chakrabarti A, Sharma A, Sood A, et al. Changing scenario of cryp- tococcosis in a tertiary care hospital in north India. Indian J Med Res 2000; 112:56-60.
74. Tharayil JG, Shankar V, Talaulikar G, et al. Epidemiology of systemic mycoses among renal-transplant recipients in India. Transplantation 2003; 75:1544-51.
75. Linden P, Williams P, Chan KM. Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections. Clin Transplant 2000; 14:329-39.
76. Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001; 33:690-9.
77. Prasad KN, Agarwal J, Nag VL, Verma AK, Dixit AK, Ayyagari A. Cryptococcal infection in patients with clinically diagnosed meningitis in a tertiary care center. Neurol India 2003; 51:364-6.
78. Vilchez R, Shapiro R, McCurry K, et al. Longitudinal study of cryp- tococcosis in adult solid-organ transplant recipients. Transpl Int 2003; 16:336-40.
79. Singh N, Alexander BD, Lortholary O, et al. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis 2007; 195:756-64.
80. Shi SH, Lu AW, Shen Y, et al. Spectrum and risk factors for invasive candidiasis and non-Candida fungal infections after liver transplantation. Chin Med J (Engl) 2008; 121:625-30.
81. Dauber JH, Paradis IL, Dummer JS. Infectious complications in pulmonary allograft recipients. Clin Chest Med 1990; 11:291-308.
82. Bach MC, Sahyoun A, Adler JL, et al. High incidence of fungus infections in renal transplantation patients treated with antilympho- cyte and conventional immunosuppression. Transplant Proc 1973;5:549-53.
83. Jabbour N, Reyes J, Kusne S, Martin M, Fung J. Cryptococcal meningitis after liver transplantation. Transplantation 1996; 61:146-9.
84. Nampoory MR, Khan ZU, Johny KV, et al. Invasive fungal infections in renal transplant recipients. J Infect 1996; 33:95-101.
85. Kanj SS, Welty-Wolf K, Madden J, et al. Fungal infections in lung and heart-lung transplant recipients: report of 9 cases and review of the literature. Medicine (Baltimore) 1996;75:142-56.
86. Schroter GP, Temple DR, Husberg BS, Weil R 3rd, Starzl TE. Cryptococcosis after renal transplantation: report of ten cases. Surgery 1976; 79:268-77.
87. Gallis HA, Berman RA, Cate TR, Hamilton JD, Gunnells JC, Stickel DL. Fungal infection following renal transplantation. Arch Intern Med 1975; 135:1163-72.
88. Watson AJ, Russell RP, Cabreja RF, Braverman R, Whelton A. Cure of cryptococcal infection during continued immunosuppressive ther- apy.Q JMed 1985;55:169-72.
89. Britt RH, Enzmann DR, Remington JS. Intracranial infection in cardiac transplant recipients. Ann Neurol 1981 ; 9:107-19.
90. Alangaden G, Chandrasekar PH, Bailey E, Khaliq Y. Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation. The Bone Marrow Transplantation Team. Bone Marrow Transplant 1994; 14:919-24.
91. Chou LS, Lewis RE, Ippoliti C, Champlin RE, Kontoyiannis DP. Cas- pofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy 2007; 27:1644-50.
92. Krcmery V Jr, Kunova A, Mardiak J. Nosocomial Cryptococcus lau- rentii fungemia in a bone marrow transplant patient after prophylaxis with ketoconazole successfully treated with oral fluconazole. Infection 1997; 25:130.
93. Mendpara SD, Ustun C, Kallab AM, Mazzella FM, Bilodeau PA, Jillella AP. Cryptococcal meningitis following autologous stem cell transplantation in a patient with multiple myeloma. Bone Marrow Transplant 2002; 30:259-60.
94. Ramchandren R, Gladstone DE. Cryptococcus albidus infection in a patient undergoing autologous progenitor cell transplant. Transplantation 2004; 77:956.
95. Rimek D, Haase G, Luck A, Casper J, Podbielski A. First report of a case of meningitis caused by Cryptococcus adeliensis in a patient with acute myeloid leukemia. J Clin Microbiol 2004;42:481-3.
96. Miniero R, Nesi F, Vai S, et al. Cryptococcal meningitis following a thrombotic microangiopathy in an unrelated donor bone marrow transplant recipient. Pediatr Hematol Oncol 1997; 14:469-74.
97. Husain S, Tollemar J, Dominguez EA, et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 2003; 75:2023-9.
98. Husain S, Alexander BD, Munoz P, et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non- Aspergillus mycelial fungi. Clin Infect Dis 2003; 37:221-9.
99. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation 2001;71:910-3.
100. US Organ Procurement and Transplantation Network, Scientific Registry of Transplant Recipients. 2007 OPTN/SRTR annual report: transplant data 1997-2006. Rockville, MD: Health Resources and Services Administration, Healthcares Systems Bureau, Division of Transplantation, 2007. Available at: http://www.ustransplant.org/ annualreports/current/. Accessed 18 November 2008.
101. Gorlach J, Fox DS, Cutler NS, Cox GM, Perfect JR, Heitman J. Identification and characterization of a highly conserved calcineurin binding protein, CBP1/calcipressin, in Cryptococcus neoformans. EMBO J 2000; 19:3618-29.
102. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000; 30:710-8.
103. Dromer F, Bernede-Bauduin C, Guillemot D, Lortholary O. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS ONE 2008; 3:e2870.
104. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination anti- fungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004;363:1764-7.
105. Hamill RJ, Sobel J, El-Sadr W, et al. Randomized double-blind trial of AmBisome (liposomal amphotericin B) and amphotericin B in acute cryptococcal meningitis in AIDS patients [abstract 1999]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1999.
106. Leenders AC, Reiss P, Portegies P, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997; 11:1463-71.
107. Pappas PG, Kauffman CA, Alexander B, et al. Prospective surveillance of invasive fungal infections (IFIs) among organ transplant recipients (OTRs) in the U.S. 2001-2006: review of TRANSNET [abstract M- 1195]. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2007:449.
108. Center for International Blood and Marrow Transplant Research. Progress report: January-December 2007. Available at: http://www.cibmtr-.org/ABOUT/ Annual-Report/Archive/index.html. Accessed 10 October 2008.
109. Graybill JR, Mitchell L, Drutz DJ. Host defense in cryptococcosis. III. Protection of nude mice by thymus transplantation. J Infect Dis 1979; 140:546-52.
110. Aguirre K, Havell EA, Gibson GW, Johnson LL. Role oftumor necrosis factor and gamma interferon in acquired resistance to Cryptococcus neoformans in the central nervous system of mice. Infect Immun 1995; 63:1725-31.
111. Decken K, Kohler G, Palmer-Lehmann K, et al. Interleukin-12 is essential for a protective Th1 response in mice infected with Cryp- tococcus neoformans. Infect Immun 1998; 66:4994-5000.
112. Kawakami K. Regulation by innate immune T lymphocytes in the host defense against pulmonary infection with Cryptococcus neofor- mans. Jpn J Infect Dis 2004;57:137-45.
113. Vecchiarelli A, Retini C, Monari C, Tascini C, Bistoni F, Kozel TR. Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect Immun 1996; 64:2846-9.
114. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophos- phamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-in- compatible transplanted SCID mice. Blood 1994; 83:2360-7.
115. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997;90:3204-13.
116. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000; 95:2754-9.
117. Ferrara JL, Krenger W. Graft-versus-host disease: the influence of type 1 and type 2 T cell cytokines. Transfus Med Rev 1998; 12:1-17.
118. Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 2006; 43:3-10.
119. van der Velden AM, Claessen AM, van Velzen-Blad H, Biesma DH, Rijkers GT. Development of T cell-mediated immunity after autol- ogous stem cell transplantation: prolonged impairment of antigen- stimulated production of γ-interferon. Bone Marrow Transplant 2007;40:261-6.
120. Singh RK, Varney ML, Ino K, Vose JM, Bierman PJ, Talmadge JE. Immune dysfunction despite high levels of immunoregulatory cyto- kine gene expression in autologous peripheral blood stem cell transplanted non-Hodgkin's lymphoma patients. Exp Hematol 2000;28:499-507.
121. Charlier C, Hart E, Lefort A, et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 2006; 57:384-410.
122. Stratta RJ. Organ and tissue donor-transmitted infection: improved prevention through better screening technologies and practices. 2008. Available at: http://www.medscape.com/viewarticle/583886. Accessed 8 January 2008.
123. Hauboldt RH, Hanson SG. 2008 U.S. organ and tissue transplant cost estimates and discussion. Brookfield, WI: Milliman, April 2008. Available at: http://www.milliman.com/expertise/healthcare/publications/rr/. Accessed 10 October 2008.
124. Pascual J, Pirsch J, Torrealba J, et al. Opportunistic infections (OI) after antibody-mediated rejection (AMR) of kidney transplants (KT) induced with alemtuzumab: a comparison between early and late AMR episodes [abstract 1449]. Am J Transplant 2008; 8(Suppl 2):563.